US7655699B1
(en)
|
1992-04-22 |
2010-02-02 |
Eisai Inc. |
Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
EP0738268B1
(en)
*
|
1993-12-22 |
2004-03-03 |
Celltech R&D Limited |
Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
US6942980B1
(en)
*
|
1995-09-01 |
2005-09-13 |
Allergan, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
US5958954A
(en)
*
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526243D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US5877207A
(en)
*
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
HUP9902645A3
(en)
|
1996-03-18 |
1999-12-28 |
Eisai Co Ltd |
Fused-ring carboxylic acid derivatives
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0915825B1
(en)
*
|
1996-06-21 |
2004-05-06 |
Allergan, Inc. |
Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
US6555690B2
(en)
*
|
1996-06-21 |
2003-04-29 |
Allergan, Inc. |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
US5773594A
(en)
|
1996-06-21 |
1998-06-30 |
Allergan |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU5330698A
(en)
*
|
1996-12-23 |
1998-07-17 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
US5760276A
(en)
*
|
1997-03-06 |
1998-06-02 |
Allergan |
Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
|
WO1998046228A1
(en)
*
|
1997-04-11 |
1998-10-22 |
Bristol-Myers Squibb Company |
Retinoid antagonists and uses thereof
|
KR20010032000A
(ko)
*
|
1997-11-12 |
2001-04-16 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
레티노이드 길항제를 이용한 티-보조 세포 제2형 중재면역 질환의 치료
|
EP1117762A4
(en)
|
1998-09-29 |
2004-02-25 |
Gamida Cell Ltd |
METHOD FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND PRECELLER CELLS
|
US6048873A
(en)
*
|
1998-10-01 |
2000-04-11 |
Allergan Sales, Inc. |
Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
|
US6403638B1
(en)
|
1998-10-01 |
2002-06-11 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
US6147224A
(en)
*
|
1998-10-01 |
2000-11-14 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
US6521641B1
(en)
*
|
1998-10-08 |
2003-02-18 |
Allergan, Inc. |
Male anti-fertility agents
|
CA2346687A1
(en)
*
|
1998-10-08 |
2000-04-13 |
Allergan Sales, Inc. |
Use of rar antagonists or inverse agonists as male anit-fertility agents
|
EP1137940A4
(en)
*
|
1998-10-23 |
2004-06-02 |
Glaxo Group Ltd |
METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS
|
US6326397B1
(en)
|
1998-11-10 |
2001-12-04 |
Hoffman-La Roche Inc. |
Retinoid antagonists and use thereof
|
US6054623A
(en)
*
|
1998-12-18 |
2000-04-25 |
Alliedsignal Inc. |
Hydroxythiol grignard reaction synthesis
|
DK1161410T3
(da)
*
|
1999-03-08 |
2004-09-20 |
Basilea Pharmaceutica Ag |
Retinoidantagonister og anvendelse deraf
|
AU4225500A
(en)
*
|
1999-04-14 |
2000-11-14 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease
|
WO2000061233A2
(en)
|
1999-04-14 |
2000-10-19 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
|
US6869959B1
(en)
|
1999-04-28 |
2005-03-22 |
Institute Of Medicinal Molecular Design Inc. |
Heterocyclic carboxylic acid derivatives
|
CA2375797A1
(en)
|
1999-06-11 |
2000-12-21 |
Allergan Sales, Inc. |
Organosilyl compounds having nuclear hormone receptor modulating activity
|
US6906057B1
(en)
|
1999-06-11 |
2005-06-14 |
Allergan, Inc. |
Methods for modulating FXR receptor activity
|
US6566372B1
(en)
*
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
WO2001016139A1
(en)
|
1999-08-27 |
2001-03-08 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
AU6941200A
(en)
|
1999-08-27 |
2001-03-26 |
Ligand Pharmaceuticals Incorporated |
8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
|
CO5200852A1
(es)
*
|
1999-09-14 |
2002-09-27 |
Lilly Co Eli |
Moduladores rxr con mejorado perfil farmacologico ceptores x de los retinoides
|
US6313168B1
(en)
*
|
1999-12-15 |
2001-11-06 |
Allergan Sales, Inc. |
Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
|
US20030114482A1
(en)
*
|
1999-12-15 |
2003-06-19 |
Maurizio Pacifici |
Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
|
US6713515B2
(en)
|
2000-09-13 |
2004-03-30 |
Bristol Myers Squibb Company |
Retinoic acid receptor antagonists as promoters of angiogenesis
|
US20030003517A1
(en)
*
|
2001-03-22 |
2003-01-02 |
Klein Elliott S. |
Methods of detecting dissociated nuclear hormone receptor ligands
|
US20020193403A1
(en)
*
|
2001-05-03 |
2002-12-19 |
Allergan Sales, Inc. |
Methods of treating hyperlipidemia
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Lxrのモジュレーター
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
EP1465982A4
(en)
*
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
|
KR101086611B1
(ko)
*
|
2002-06-20 |
2011-11-23 |
프리메라디엑스, 인크. |
폴리뉴클레오티드 감지와 정량을 위한 기구
|
AU2003249534A1
(en)
*
|
2002-08-13 |
2004-02-25 |
Warner-Lambert Company Llc |
6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
|
US7105566B2
(en)
*
|
2002-10-22 |
2006-09-12 |
Allergan, Inc. |
Methods of treatment during vascular procedures
|
FR2847255B1
(fr)
*
|
2002-11-18 |
2006-11-17 |
Galderma Res & Dev |
Nouveaux ligands antagonistes des recepteurs rars, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
EP1565433B1
(en)
*
|
2002-11-18 |
2007-03-14 |
Galderma Research & Development, S.N.C. |
Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
|
US20050026950A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
|
US20050026949A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoids without regard to body weight
|
WO2005011667A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoid components
|
US20050026957A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of treating nodulocystic acne
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
EP1701934B1
(en)
*
|
2003-12-26 |
2009-02-25 |
Allergan, Inc. |
DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
|
AU2005209201B2
(en)
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US20050244472A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
EP1773350B1
(en)
*
|
2004-07-12 |
2013-05-29 |
Allergan, Inc. |
Opthalmic compositions for treating ophthalmic conditions
|
EP1621191A1
(en)
*
|
2004-07-29 |
2006-02-01 |
Werner Bollag |
Treatment of inflammatory diseases by RXR Antagonists
|
WO2006030442A2
(en)
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
JP2009510114A
(ja)
|
2005-09-30 |
2009-03-12 |
ビテ ファーマシューティカルズ, インコーポレイテッド |
特定のrxrアゴニストによる癌治療
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
TR201819157T4
(tr)
*
|
2006-05-16 |
2019-01-21 |
Io Therapeutics Llc |
Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US9642845B2
(en)
*
|
2007-02-28 |
2017-05-09 |
University Of Kentucky Research Foundation |
Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
KR101041281B1
(ko)
*
|
2009-05-18 |
2011-06-14 |
주식회사 니프코코리아 |
자동차의 에어벤트 다이얼
|
MX361709B
(es)
|
2009-11-09 |
2018-12-07 |
Allergan Inc |
Composiciones y metodos para estimular el crecimiento del cabello.
|
AU2012262081A1
(en)
|
2011-06-03 |
2014-01-09 |
Allergan, Inc. |
Targeted delivery of retinoid compounds to the sebaceous glands
|
CN104114171A
(zh)
|
2011-12-13 |
2014-10-22 |
Io治疗公司 |
使用rxr激动剂的自身免疫紊乱的治疗
|
CN104204192A
(zh)
|
2012-02-13 |
2014-12-10 |
加米达细胞有限公司 |
间充质干细胞调理的基质及其产生和使用方法
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US20140094512A1
(en)
|
2012-10-02 |
2014-04-03 |
Nikolas Gunkel |
Method of modulating the degree of adipose tissue deposited intramuscularly
|
JP6511401B2
(ja)
|
2013-02-15 |
2019-05-15 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
持続型薬物送達インプラント
|
ES2941769T3
(es)
|
2015-10-31 |
2023-05-25 |
Io Therapeutics Inc |
Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de RXR y hormonas tiroideas
|
EP3380086B1
(en)
|
2015-11-25 |
2021-10-13 |
IO Therapeutics, Inc. |
Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
|
CA3013411A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Galderma Research & Development |
Novel biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
|
CN109069645A
(zh)
|
2016-03-10 |
2018-12-21 |
Io治疗公司 |
用rxr激动剂与甲状腺激素的组合的肌肉疾病的治疗
|
EP4166160A1
(en)
|
2016-03-10 |
2023-04-19 |
IO Therapeutics, Inc. |
Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
|
WO2017152725A1
(zh)
*
|
2016-03-11 |
2017-09-14 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
CN107176945B
(zh)
*
|
2016-03-11 |
2021-06-08 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
EP3468600A4
(en)
*
|
2016-06-10 |
2019-11-13 |
IO Therapeutics, Inc. |
RETINOID COMPOUNDS AND RELECTIVE REXINOIDS OF THE RECEPTOR AND IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER
|
CA3069676A1
(en)
|
2017-07-13 |
2019-01-17 |
Io Therapeutics, Inc. |
Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
|
NZ761401A
(en)
|
2017-08-31 |
2022-11-25 |
Io Therapeutics Inc |
Rar selective agonists in combination with immune modulators for cancer immunotherapy
|
CA3076373A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
Treatment of disease with esters of selective rxr agonists
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
CA3242046A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist and taxanes in treating her2+ cancers
|
WO2023108015A1
(en)
|
2021-12-07 |
2023-06-15 |
Io Therapeutics, Inc. |
Use of an rxr agonist in treating drug resistant her2+ cancers
|